Page last updated: 2024-10-22

aniracetam and Multiple Sclerosis

aniracetam has been researched along with Multiple Sclerosis in 1 studies

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Groom, AJ1
Smith, T1
Turski, L1

Other Studies

1 other study available for aniracetam and Multiple Sclerosis

ArticleYear
Multiple sclerosis and glutamate.
    Annals of the New York Academy of Sciences, 2003, Volume: 993

    Topics: Animals; Brain Stem; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory

2003